General MedicationsORALGeneric
KAFOCIN
CEPHALOGLYCIN
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview KAFOCIN is listed in Drugs@FDA under application 050219 (NDA).
Marketing status: Discontinued Active ingredient CEPHALOGLYCIN Form and strength CAPSULE;ORAL - 250MG Sponsor LILLY Submission history Latest submission status date: 1970-06-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview KAFOCIN is listed in Drugs@FDA under application 050219 (NDA). Marketing status: Discontinued Active ingredient CEPHALOGLYCIN Form and strength CAPSULE;ORAL - 250MG Sponsor LILLY Submission history Latest submission status date: 1970-06-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.